Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial

Clinical trial NCT07332351 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07332351
Sponsor: University of Washington
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Muscle Invasive Bladder Urothelial Carcinoma Stage II Bladder Cancer AJCC v8 Stage IIIA Bladder Cancer AJCC v8

Start date: 2026-09-01
Primary completion: 2027-01-01
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.